AI Agent Calibrates Six‑Qubit Chip, Improves Four of Forty Measurements

GPT‑5.6 Sol performed calibration of four qubits on a new MIT chip on September 8. Researchers intervened in only 4 of 40 target measurements to improve results. The agent, guided by OpenAI’s description of graduate student Beatrice Yankelevich’s work, used the Codex system to control measurements on a separate chip with six superconducting qubits.

Calibration sets the chip before experiments: the outcome of one measurement becomes the

🔗 Read original →

Philanthropists urged to fund low‑cost gerotherapy trials

On September 7, Fight Aging! published an essay by Reason explaining why testing a cheap therapy can cost far more than the therapy itself. He proposes that wealthy philanthropists fund early clinical programs to generate data. Gerotherapy targets biological aging processes and aims to reduce the risk of multiple age‑related diseases. The compound may be available in clinics, but its effect on aging must be established in a dedicated clinical trial.

In such a trial the participant group and the outcome to be measured—disease, physical function, or a combination—are defined in advance. For interventions that merely slow aging, Reason notes that observation must last at least five years to detect changes in age‑related disease incidence and mortality. He explains the difficulty with patent economics: a patent gives the developer exclusive sales rights and helps recoup R&D costs, whereas a cheap, easily copied therapy has weak patent protection; the trial can still be expensive, and investors have little incentive to pay because any supplier could benefit from the results.

“Interventions that could potentially be used against aging may remain on the market for decades without a sufficiently rigorous attempt to determine whether they actually treat aging and how well.” The essay also considers lowering medical‑regulation costs, medical tourism, and self‑experiment communities. According to the author, these routes broaden access to procedures, but reliable open data still require an organized clinical program. An article by an international geroscience working group explains why such a program needs time and money. Researchers first decide who to include in the trial and which treatment outcome to measure. Slow age‑related decline in physical function is only visible after long observation of large groups.

Scientists have not yet agreed on a universal biomarker—a measurable indicator in lab tests—that could signal aging. Therefore the price of the drug and the price of proof are separate quantities. Seeking early markers that could shorten the validation period is aided by the AFAR FAST program, which analyses samples from completed trials. Reason proposes that wealthy philanthropists fund the initial clinical programs for affordable candidates. In his model, philanthropists finance the trial data, which any supplier of the therapy could use.

🔗 Read original →

GPN-Star ranks DNA variants using cross‑species evolutionary constraints

GPN-Star compares a human DNA segment with the same segment across other species to estimate the evolutionary constraint of each single‑letter substitution. It builds a multiple‑sequence alignment of genomes and a phylogenetic tree that shows how closely related the species are. The model was described in Nature, September 9, 2026.

During training GPN-Star masks one DNA letter and predicts it from the surrounding human bases and the corresponding positions in other species, weighting closer relatives more heavily according to branch distances. The output is a probability for each possible base, from which an evolutionary‑constraint score is derived. Separate versions were trained on vertebrate, mammalian and primate alignments.

The vertebrate‑aligned version performed best at identifying substitutions in protein‑coding regions and rare high‑impact variants, whereas the mammalian and primate versions were stronger on regulatory regions that control gene expression. In practice the authors applied GPN‑Star to 34 quantitative traits from the UK Biobank, analysing 161,822 participants of European ancestry.

They added three GPN‑Star scores to the DeepRVAT statistical method, which searches for trait‑associated genes using rare variants. Across three runs the

🔗 Read original →

Blood cell reprogramming erases DNA methylation age marks

Researchers reprogrammed blood cells from 99 healthy donors into induced pluripotent stem cells (iPSCs) to test whether DNA methylation age signatures persist after reprogramming. They published their findings on 8 September.

Starting with peripheral blood mononuclear cells (PBMCs), they obtained 88 iPSC lines from donors aged 22–92 years after quality control. They retained 67 matched pairs of original blood and iPSC samples for direct methylation comparison.

In the original blood, epigenetic clocks showed higher methylation age with older donors, but in the iPSCs the age correlation disappeared across all five clock calculations. A genome‑wide analysis of all measured DNA sites, including those outside the clock sets, confirmed that age‑related signals were present in blood cells but absent in iPSCs.

The team also examined methQTL—statistical links between DNA variants and methylation levels—finding some shared between blood and iPSCs and some specific to each cell state, indicating that genetic influences on methylation differ after reprogramming. Consequently, to study blood‑specific methylation age patterns, the original blood sample is required because fully reprogrammed iPSCs carry a different methylation landscape.

🔗 Read original →

PromptBio releases preprint on PromptGenie system for biomedical computation tracking

On September 6, the PromptBio team posted a preprint on bioRxiv describing PromptGenie, a system for biomedical data research. The authors explain how it turns a research question into a plan, code, execution, and records that allow verification of the computational workflow. A biomedical question is transformed into output through a series of decisions: what data to use, which method to test a hypothesis, how to perform the calculation, and how to interpret results.

When these decisions reside in separate files, services, and email threads, it is hard to see from a final table or figure which data and choices led to it. In the preprint, the authors call PromptGenie a system that receives a research goal and available context, builds a plan of dependent steps, and adjusts subsequent steps based on intermediate results or errors. Before a major decision, the researcher can review and edit the plan.

The system then invokes a ready-made method or writes code, runs the calculation, and passes the result to the next step. Authors describe a journal where the plan and its modifications, data sources and references, parameters, execution environment details,

🔗 Read original →

Suppressing MEOX1 improves cardiac reprogramming after heart attack in mice

On September 8, researchers published in Circulation a study in which they treated mice after myocardial infarction with a cocktail of cardiac‑reprogramming factors together with a short RNA designed to suppress the MEOX1 gene.

Six weeks later, the mice that received MEOX1‑suppressing RNA had more cells expressing cardiac‑muscle markers, a smaller scar, and a markedly improved ejection fraction (38.1% versus 28.85% in the control group). The number of spontaneously contracting cells was also increased roughly about fourfold.

Further analysis showed that MEOX1 drives a scar‑promoting program and is upregulated by the profibrotic signal TGF‑β1; reducing its activity allowed fibroblasts to adopt a cardiomyocyte fate, whereas restoring MEOX1 or using a RNA‑resistant version abolished the benefit.

The same combination of reprogramming factors and MEOX1 inhibition also raised the proportion of cardiac‑muscle‑positive cells in cultured human fibroblasts, supporting the idea that blocking MEOX1 helps convert scar‑forming cells into functional heart muscle.

🔗 Read original →

FDA talks preventive therapies for multiple age-related diseases at H-SPAN summit

On September 9, the H‑SPAN longevity biotech summit hosted a panel on how the FDA should evaluate preventive therapies aimed at several age‑related diseases. The discussion built on questions raised in the July H‑SPAN summit report about which disease to target first and what metric to use to prove benefit.

Robert Kalesnik-Orshulak, who leads regulatory affairs at Retro Biosciences, argued that companies should start with a single indication, obtain early results, and then expand the label to other aging‑related conditions. He suggested using the FDA’s accelerated approval pathway, where a surrogate endpoint could serve as the basis for a decision.

David Fox, an FDA regulatory lawyer and co‑author of the Thrive Act, countered that testing a therapy meant to delay multiple chronic diseases before a serious diagnosis requires large cohorts, long follow‑up, and especially rigorous safety assessment. He noted that his Thrive Act outlines a staged evidence framework for prevention in people without a severe diagnosis.

Lowell Zeta, introduced as the FDA deputy commissioner for strategy and acting chief of staff, invited industry to submit data and proposals. He pointed to **Operation

🔗 Read original →

Experts propose labeling aging a 'metadisease' to streamline clinical trials

At the H-SPAN summit on 9 September, anatomist Antonney Chok urged that aging be described as a “metadisease” — a biological process that underlies several age‑related conditions. He argued that this framing would help clinical trials assess interventions targeting aging biology by measuring a set of related outcomes.

The discussion built on the July report of the H-SPAN summit, which devoted its second day to clinical endpoints and FDA regulations. Panelists asked what a single trial should test if a therapy alters the overall aging process, noting that endpoints must be predefined and measurable.

Chok explained that because aging drives multiple pathologies, an intervention will need a bundle of linked metrics rather than a single disease‑specific endpoint. He highlighted cellular senescence — the state in which cells cease dividing and alter tissue function — as a central mechanism in his model.

To enable one trial to evaluate several results, Chok proposed assigning an ICD code to aging as a metadisease. He also suggested creating a federal institute of gerontology alongside the National Institute on Aging to unite researchers who currently work in cancer, heart disease, or Alzheimer’s programs around shared aging biology.

🔗 Read original →

Jay Olshansky Proposes Measuring Medical Success by Years of Independent Living

At the H-SPAN meeting on the economics of aging on September 9, aging researcher Jay Olshansky called the later years of life a 'red zone' where the risk of frailty and disability rises rapidly. He proposed measuring medical progress by how many years of independent living can be preserved.

In the XX век, public health and medicine shifted most deaths from younger to older ages. Olshansky’s next step is to delay the period when frailty, disability, and disease accumulate together with age.

In his model, the 'red zone' is the late-life period with rapidly increasing risk of these conditions. Treating a single diagnosis may avert one threat but leaves time to encounter other age‑related damages, as he summarized with the formula: 'Knock down one disease — two rise; knock down two — four.'

By targeting the processes that cause damage to accumulate with age, onset of multiple age‑related impairments could be postponed and frailty years reduced. Success is measured in years during which a person maintains mobility, clear thinking, and the ability to live without constant assistance.

The

🔗 Read original →

H-SPAN Summit Links NIH Grants, Lab Timing, and Payer Decisions

At the H-SPAN summit on longevity policy held on September 9, Felipe Sierra, Catherine Kachorovski, and Michael Rinkel discussed how grants, clinical data, and payer decisions form a chain. The US National Institutes of Health (NIH) allocate grants, labs depend on their timing, and insurers or government programs decide whether to pay for treatment based on trial data.

Felipe Sierra, former director of the National Institute on Aging’s Biology of Aging division, explained why his division lacked funding: the number of applications grew while the budget stayed flat. He said he did not ask for more money but wanted NIH to spend its funds elsewhere—specifically on aging‑as‑a‑common‑risk‑factor research already pursued by other NIH institutes. He urged their leaders to redirect their own budgets toward such projects.

Catherine Kachorovski, a professor at the University of Michigan, showed how a grant delay affects a lab. Her application scored in the top 5%; she was initially told she would be funded, but the money was held up because part of the budget had already been pledged to five‑year grants. Universities cut graduate‑student admissions, labs lost funding, and for her lab the delay influenced which staff she could retain.

Michael Rinkel, COO of biotech firm Life Biosciences, shifted the talk to drugs. Phase I trials give early safety and dosage data; later studies test possible efficacy and gather more safety information. He noted that each year 200–300 drug candidates pass Phase I but fail Phase II, so he opposes releasing a drug after only early safety checks.

In the spring the New Hampshire House of Representatives approved centers where drugs can be used after Phase I. This makes Rinkel’s debate practical: payers can decide reimbursement based on data collected after early safety testing. He also warned that lengthy validation is costly, and an analysis of cheap gene‑therapy trials showed why a therapy that is easy to copy may attract no investor for such study—its benefits would be available to all providers.

🔗 Read original →

Single IV injection of dual‑gene AAV9 extends lifespan in Sandhoff cat model

In a study published Science Translational Medicine, September 9, researchers used a single intravenous injection of an AAV9 vector carrying both HEXA and HEXB genes to treat asymptomatic kittens with a feline model of Sandhoff disease. The vector aims to restore the HexA enzyme needed to break down the lipid GM2 that accumulates in lysosomes.

Untreated animals survived a median of 4.3 months, while low‑dose kittens lived 8.3 months on average. High‑dose treatment extended median survival to 12.4 months, and one cat reached 16 months.

Tremor appeared in untreated kittens around 2.4 months of age. No tremor was observed in the high‑dose group, whereas tremor was delayed in three of four low‑dose kittens.

Sixteen weeks after the high‑dose injection, MRI showed partial preservation of brain structure and CSF levels of neurodegeneration markers were reduced. HexA activity reached approximately 70% of normal in the hindbrain and 120% in the spinal cord.

The liver contained the highest vector copy number, but HexA activity there did not exceed 9% of normal levels. Over longer periods, brain architecture and inflammatory signs in some treated animals began to resemble those of untreated controls.

🔗 Read original →

Review of 101 Species Highlights DNA Maintenance, Tissue Renewal, Stress Resistance

On 8 September the journal Aging published a review of 101 species with maximum lifespans starting at 250 years, comprising 11 animals and 90 plants.

The authors compared lifespan differences among individuals of the same species and between different species, asking why individuals of a long‑lived species vary in longevity and how these species differ from shorter‑lived ones; they sought processes that recur in both comparisons.

In both comparisons three common directions emerged: DNA maintenance (repairing damage), stem cell properties (enabling cells to divide and generate different tissue types), and stress resistance (helping cells cope with unfavorable conditions and associated harm).

When comparing species, the authors also examined regeneration and tumor suppression; in hydra regeneration replaces all body cells roughly every twenty days, while in common pine and ginkgo root‑growth zone cells retain differentiation ability with age, unlike the shorter‑lived Arabidopsis where this ability declines.

The authors link the three common directions to early developmental stages and germ cells, concluding with the phrase: “Staying young, it seems, is a strategy for long life.”

🔗 Read original →